Literature DB >> 26864378

Correctors Rescue CFTR Mutations in Nucleotide-Binding Domain 1 (NBD1) by Modulating Proteostasis.

Miquéias Lopes-Pacheco1,2, Inna Sabirzhanova1, Daniele Rapino1, Marcelo M Morales2, William B Guggino1, Liudmila Cebotaru3.   

Abstract

We evaluated whether small molecule correctors could rescue four nucleotide-binding domain 1 (NBD1) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (A455E, S492F, ΔI507, and R560T). We first transfected Cos-7 cells (green monkey kidney cells) with A455E, S492F, ΔI507, or R560T and created HEK-293 (human embryonic kidney cells) cell lines stably expressing these CFTR mutations. The mutants showed lowered protein expression, instability at physiological temperature, and rapid degradation. After treatment with correctors CFFT-002, CFFT-003, C3, C4, and/or C18, the combination of C18+C4 showed the most correction and resulted in increased CFTR residing in the plasma membrane. We found a profound decrease in binding of CFTR to histone deacetylases (HDAC) 6 and 7 and heat shock proteins (Hsps) 27 and 40. Silencing Hsp27 or 40 rescued the mutants, but no additional amount of CFTR was rescued when both proteins were knocked down simultaneously. Thus, CFTR mutations in NBD1 can be rescued by a combination of correctors, and the treatment alters the interaction between mutated CFTR and the endoplasmic reticulum machinery.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  correctors; cystic fibrosis; mutagenesis; protein misfolding; proteostasis network

Mesh:

Substances:

Year:  2016        PMID: 26864378      PMCID: PMC5557405          DOI: 10.1002/cbic.201500620

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  38 in total

1.  HDAC6-p97/VCP controlled polyubiquitin chain turnover.

Authors:  Cyril Boyault; Benoit Gilquin; Yu Zhang; Vladimir Rybin; Elspeth Garman; Wolfram Meyer-Klaucke; Patrick Matthias; Christoph W Müller; Saadi Khochbin
Journal:  EMBO J       Date:  2006-06-29       Impact factor: 11.598

2.  Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Authors:  Patrick A Flume; Theodore G Liou; Drucy S Borowitz; Haihong Li; Karl Yen; Claudia L Ordoñez; David E Geller
Journal:  Chest       Date:  2012-09       Impact factor: 9.410

3.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

4.  Rescuing Trafficking Mutants of the ATP-binding Cassette Protein, ABCA4, with Small Molecule Correctors as a Treatment for Stargardt Eye Disease.

Authors:  Inna Sabirzhanova; Miquéias Lopes Pacheco; Daniele Rapino; Rahul Grover; James T Handa; William B Guggino; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2015-06-19       Impact factor: 5.157

5.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

6.  The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment.

Authors:  Y Yang; S Janich; J A Cohn; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

Review 7.  CFTR and chaperones: processing and degradation.

Authors:  Margarida D Amaral
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

8.  Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function.

Authors:  Adrian W R Serohijos; Tamás Hegedus; Andrei A Aleksandrov; Lihua He; Liying Cui; Nikolay V Dokholyan; John R Riordan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-27       Impact factor: 11.205

9.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function.

Authors:  Tsukasa Okiyoneda; Guido Veit; Johanna F Dekkers; Miklos Bagdany; Naoto Soya; Haijin Xu; Ariel Roldan; Alan S Verkman; Mark Kurth; Agnes Simon; Tamas Hegedus; Jeffrey M Beekman; Gergely L Lukacs
Journal:  Nat Chem Biol       Date:  2013-05-12       Impact factor: 15.040

10.  Correcting the cystic fibrosis disease mutant, A455E CFTR.

Authors:  Liudmila Cebotaru; Daniele Rapino; Valeriu Cebotaru; William B Guggino
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

View more
  14 in total

1.  Ubiquitination of disease-causing CFTR variants in a microsome-based assay.

Authors:  Samuel K Estabrooks; Jeffrey L Brodsky
Journal:  Anal Biochem       Date:  2020-07-01       Impact factor: 3.365

Review 2.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

3.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

4.  High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel.

Authors:  Valeria Tomati; Emanuela Pesce; Emanuela Caci; Elvira Sondo; Paolo Scudieri; Monica Marini; Felice Amato; Giuseppe Castaldo; Roberto Ravazzolo; Luis J V Galietta; Nicoletta Pedemonte
Journal:  J Biol Chem       Date:  2017-11-20       Impact factor: 5.157

Review 5.  Small Hsps as Therapeutic Targets of Cystic Fibrosis Transmembrane Conductance Regulator Protein.

Authors:  Stéphanie Simon; Abdel Aissat; Fanny Degrugillier; Benjamin Simonneau; Pascale Fanen; André-Patrick Arrigo
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

Review 6.  CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.

Authors:  Miquéias Lopes-Pacheco
Journal:  Front Pharmacol       Date:  2016-09-05       Impact factor: 5.810

7.  Phosphorylation of the Chaperone-Like HspB5 Rescues Trafficking and Function of F508del-CFTR.

Authors:  Fanny Degrugillier; Abdel Aissat; Virginie Prulière-Escabasse; Lucie Bizard; Benjamin Simonneau; Xavier Decrouy; Chong Jiang; Daniela Rotin; Pascale Fanen; Stéphanie Simon
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

8.  Phenotyping of Rare CFTR Mutations Reveals Distinct Trafficking and Functional Defects.

Authors:  Marjolein Ensinck; Liesbeth De Keersmaecker; Lise Heylen; Anabela S Ramalho; Rik Gijsbers; Ricard Farré; Kris De Boeck; Frauke Christ; Zeger Debyser; Marianne S Carlon
Journal:  Cells       Date:  2020-03-19       Impact factor: 6.600

Review 9.  CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.

Authors:  Miquéias Lopes-Pacheco
Journal:  Front Pharmacol       Date:  2020-02-21       Impact factor: 5.810

10.  Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery.

Authors:  Marcello Carotti; Martina Scano; Irene Fancello; Isabelle Richard; Giovanni Risato; Mona Bensalah; Michela Soardi; Dorianna Sandonà
Journal:  Int J Mol Sci       Date:  2020-03-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.